- Home
- GLTO vs AQMS Comparison
GLTO vs AQMS Comparison
Compare GLTO & AQMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- AQMS
- Stock Information
- Founded
- GLTO 2011
- AQMS 2014
- Country
- GLTO Denmark
- AQMS United States
- Employees
- GLTO N/A
- AQMS N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- AQMS Metal Fabrications
- Sector
- GLTO Health Care
- AQMS Industrials
- Exchange
- GLTO Nasdaq
- AQMS Nasdaq
- Market Cap
- GLTO 4.5M
- AQMS 5.2M
- IPO Year
- GLTO 2020
- AQMS 2015
- Fundamental
- Price
- GLTO $3.34
- AQMS $3.60
- Analyst Decision
- GLTO Buy
- AQMS Buy
- Analyst Count
- GLTO 1
- AQMS 1
- Target Price
- GLTO $10.00
- AQMS $30.00
- AVG Volume (30 Days)
- GLTO 19.6K
- AQMS 54.1K
- Earning Date
- GLTO 08-05-2025
- AQMS 08-13-2025
- Dividend Yield
- GLTO N/A
- AQMS N/A
- EPS Growth
- GLTO N/A
- AQMS N/A
- EPS
- GLTO N/A
- AQMS N/A
- Revenue
- GLTO N/A
- AQMS N/A
- Revenue This Year
- GLTO N/A
- AQMS N/A
- Revenue Next Year
- GLTO N/A
- AQMS $550.00
- P/E Ratio
- GLTO N/A
- AQMS N/A
- Revenue Growth
- GLTO N/A
- AQMS N/A
- 52 Week Low
- GLTO $2.01
- AQMS $3.40
- 52 Week High
- GLTO $14.88
- AQMS $50.22
- Technical
- Relative Strength Index (RSI)
- GLTO 45.88
- AQMS 36.80
- Support Level
- GLTO $3.26
- AQMS $3.45
- Resistance Level
- GLTO $3.48
- AQMS $4.18
- Average True Range (ATR)
- GLTO 0.15
- AQMS 0.34
- MACD
- GLTO -0.00
- AQMS 0.05
- Stochastic Oscillator
- GLTO 51.52
- AQMS 13.76
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.